FDA IND clearance is a major catalyst for a micro-cap biotech — it removes regulatory gate risk and sets a clear timeline to pivotal data in ~6 months. Traders should watch for enrollment updates and potential partnership interest given the needle-free differentiation in a large market.
Price Chart
Executive Summary
Nasus Pharma announced FDA clearance of its IND application for NS002, an intranasal epinephrine powder for anaphylaxis, allowing the company to initiate clinical studies. A pivotal study is planned for Q4 2026 with topline data expected in Q1 2027. This is a significant regulatory milestone for a clinical-stage company with a $40M market cap, de-risking the lead asset and enabling a clear path to pivotal data.
Key Facts
- FDA cleared IND for NS002 (intranasal epinephrine powder for anaphylaxis)
- Pivotal study planned for Q4 2026; topline data expected Q1 2027
- Phase 2 data showed NS002 achieved 100 pg/mL plasma epinephrine threshold with median T100 of 1.69 min vs 3.47 min for EpiPen
- CEO cited a growing $2 billion market opportunity
Financial Impact
No financial figures reported; clinical-stage company with no revenue. Market opportunity cited as $2 billion by management.
Risk Factors
- Pivotal study may fail to replicate Phase 2 results or meet FDA endpoints
- FDA may require additional studies before approval
- Company has no approved products and limited cash runway (not disclosed in filing)
- Competition from existing autoinjectors (EpiPen) and other needle-free alternatives in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-042488 |
| Exhibit: ex99-1.htm | 0001493152-26-042488 |
| Document: 0001493152-26-042488-index-headers.html | 0001493152-26-042488 |
| Document: 0001493152-26-042488-index.html | 0001493152-26-042488 |
| Document: 0001493152-26-042488.txt | 0001493152-26-042488 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 17d ago | 6-K | $3.51 | awaiting T+20 | — | $3.41 (−2.71%) |
Sep 23, 2026 4w ago | 3 | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.41 (−6.18%) |
Sep 18, 2026 5w ago | 424B5 | $3.44 $3.21 | ▲ +6.83% | ▲ +5.92% | $3.41 (+0.73%) |
Sep 14, 2026 6w ago | 6-K | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.41 (−6.44%) |
Sep 14, 2026 6w ago | EFFECT | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.41 (−6.44%) |
Aug 21, 2026 9w ago | EFFECT | $4.00 $3.44 | ▼ −14.00% | ▼ −13.47% | $3.41 (−14.63%) |
Aug 19, 2026 9w ago | 6-K | $3.84 $3.53 | ▼ −8.07% | ▼ −6.12% | $3.41 (−11.07%) |
Aug 17, 2026 10w ago | 6-K | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.41 (−7.70%) |
Aug 17, 2026 10w ago | Press Release | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.41 (−7.70%) |
Apr 1, 2026 29w ago | EFFECT | $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $3.41 (−33.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers